A Phase II Trial of Pembrolizumab Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC
Phase of Trial: Phase II
Latest Information Update: 22 May 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 15 May 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 15 May 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.